Lumateperone

🧮 Dose calculator

Schizophrenia · Regimen source: FDA Caplyta · 2.1

• • Moderate/severe hepatic impairment or moderate CYP3A4 inhibitors: 21 mg; strong CYP3A4 inhibitors: 10.5 mg. FDA Caplyta · 2.3FDA Caplyta · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Caplyta · 8.1

  “Risk Summary Neonates exposed to antipsychotic drugs during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see Clinical Considerations ).”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Caplyta · 8.2

  “Risk Summary Lumateperone and its metabolites are present in human breast milk in low amounts.”

• 👶 ChildrenDangerous / avoid

  Boxed warning in the label about children. FDA Caplyta · Boxed Warning

  “Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies.”

• 👴 Older adultsDangerous / avoid

  Label: serious warning or avoid in older adults. FDA Caplyta · Boxed Warning

  “Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Caplyta · 8.3

  “Infertility Based on findings from animal studies, lumateperone may impair male and female fertility [see Nonclinical Toxicology (13.1) ].”